Evidence map›Paper›PMID 33912804›Full record

ArticleAME case reports2021

Fiducial marker migration following computed tomography-guided placement in the liver: a case report.

Karishma Khullar, Survandita Tara Dhawan, John Nosher, Salma K Jabbour

Open access · diamondAbstract readCase Reports
In one paragraph

Article in AME case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Are liver contour and bone fusion comparable to fiducials for IGRT in liver SBRT?Technical innovations & patient support in radiation oncology · 2023
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Karishma KhullarDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA.
Survandita Tara DhawanRutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA.
John NosherDepartment of Radiology, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.
Salma K JabbourDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA.
Rutgers, The State University of New Jersey · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiation therapy for liver tumors has been shown to provide a local control and overall survival benefit in patients with primary or oligometastatic liver tumors. However, accurate delineation of the target volume in intraabdominal tumors can be limited by diaphragmatic motion. In addition to image guidance during radiation therapy, computed tomography (CT)-guided fiducial marker placement can improve the accuracy of radiation treatment and optimize tumor control. Fiducial marker placement is often indicated in stereotactic body radiation therapy (SBRT) due to the ablative doses used as well as in proton therapy given that these markers are clearly visible on orthogonal kV image guidance and studies have suggested that their placement in liver tumors offers improved local control. However, fiducial marker migration is a rare risk associated with fiducial placement for which literature remains scarce. We report two separate cases of fiducial marker migrations from the liver into the inferior vena cava and right atrium which occurred following CT-guided placement without any resultant toxicity. Imaging using contrast-enhanced or volume navigation ultrasound techniques during fiducial marker deployment may mitigate the risk of fiducial marker migration and potential end-organ injury. Alternative techniques for motion management such as inspiratory or expiratory breath hold or use of residual lipiodol on imaging in patients who have undergone transarterial chemoembolization (TACE) should be considered as well to avoid potential complications from fiducial marker placement.

Indexed as

Fiducial markershepatocellular carcinoma (HCC)liver oligometastasesstereotactic body radiation therapy (SBRT)

Identifiers

PMID33912804
PMCPMC8060155
OpenAlexW3154184788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.